TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time of magnesium sulfate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymph node number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achieving pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change in Physician Wart Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients With a Confirmed Case of Transfusion-transmitted Chikungunya Virus or Dengue Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients With Any Transfusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Sorafenib Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in anterior chamber depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proper Placement of the Subglottic Suction Lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ease of Placement of the Subglottic Suction Lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retention of the Subglottic Suction Lumen Within the Tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Protection of the Subglottic Suction Lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effective Subglottic Suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: detection rate of bleeding cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pre-dialysis anti-Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Procedural Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline of glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vital signs (12-lead ECG, PEFR, FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TrA muscle activation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GRF (ground reaction force)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recurrent heart failure-related hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Time to ambulatory worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Anderson - Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absence of Mental Stress-induced Myocardial Ischemia (MSIMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Mental Stress-induced Myocardial Ischemia (MSIMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of major bowel dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain reactivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multi marker test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Anti-oxidant Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of teeth vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone marrow mast cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Rate of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plantar pressure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic concentration of ceftriaxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Activity Rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic uptake and washout of [18F]MK-9470
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease specific hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: plasma TMC278 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry eye signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcomes associated with TIPS usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterotopic Ossification recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Agreed to Participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With a Clinical Phenotype Warranting Alternative Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of Genasense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects who have returned to room air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change of subjects return to baseline oxygen requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS-A Score Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Irbesartan concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude of low-frequency fluctuation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in State Hope Scale (SHS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerability of Pirfenidone
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion Ratio of Tacrolimus Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily alimentary intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Impact of Event Scale (IES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in The Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in The Profile of Mood States - Short Form (POMS-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of PDPH (Post-Dural Puncture Headache)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall survival to 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Low grade inflammation in maternal and cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: within-participant difference in fecal energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of romidepsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ElectroCardioGram (ECG) sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: whole operation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total active motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100-Day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Infarct size (in % of LV mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Testosterone levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Pain following Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAART adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Severity of Illness - Sequential Organ Failure Assessment (SOFA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Veterans Crisis Line (VCL) Contact Events
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of patients achieving target vancomycin trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children off intravenous dextrose support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving normal angle of forward flexion and painless range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With HIV-1 RNA ≥50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With One or More Adverse Events (AEs) up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: change in thromboelastography components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local skin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Steady-state White Blood Cell Cystine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of aspirated secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cognitive measure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MAS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Long-term safety of digna P144 cream
Endpoint domain: Adverse events/effects
Primary endpoint: number of vaccinated patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in the total score of RLSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I (CGI-Improvement)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of pediatric HOT patients completing 1 year follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Amputation free survival (AFS)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Cardiovascular hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in peak oxygen consumption (VO2) assessed by CPET after RT234 dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitor titre <0.6 BU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental recovery of FVIII in the normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Half-life of FVIII > 7 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amputation-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in total plaque volume (mm3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Agatston Score (Agatston units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in segmental stenosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Photoplethysmography derived amplitude-baseline ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Fracture Union Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Feasibility of monitoring patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) changes at Hip and Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from examination to spontaneous onset of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Locoregional relapse
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) 365 Days Following the Last Study Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relapse rate of acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to acne relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Worst-itching Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Itch Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Secondary attack rate among close household contacts
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of volunteers who become parasitemic with temperature ≥37.5°C or history of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence and frequency of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Signal Change in fMRI BOLD Signal in Right Inferior Frontal Cortex (rIFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Signal Change in fMRI BOLD Signal in Presupplementary Motor Area (Pre-SMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in knee flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of patients achieving response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Training Measured by Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Terminal phase half-life for Recombinant Antihemophilic Factor (rAHF-PFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of Heat Shock Protein 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of psoriasis and vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of Severe-range Hypertension After Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Liver Iron Concentration (LIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in LIC Adjusted by Transfusional Iron Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PIVA score correlation with hemodynamic monitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Deviation of 24-hour Blood Glucose Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of serum anti-PCV-1 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diverticulitis relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Number of beds using ethanol treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Observance of GINA criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body core temperature of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation Malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor necrosis factor alfa (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acne Lesion Counts (Absolute Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Impact of biopsy on pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Impact of biopsy on delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Minimum diameter of the left main bronchus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breastfeeding outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of catheter surface colonised by biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Disease-free Survival (DFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Wechsler Intelligence Scale Processing Speed Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relative Dose Intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of treatment exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of subjects with permanent discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Protection of heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protection of intestinal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CAARS:INV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinical characteristics of the peri implant mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial time course of Asymmetric dimethyl arginine (ADMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ratings of perceived exertion (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contractility of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatiguability of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of NeuroMuscularJunction disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reliability (specificity and sensitivity) of Train-Of-Four
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of osteoprotegerin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydration Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanin Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes